Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04003896 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate Abemaciclib in Advanced Biliary Tract Carcinoma
A Phase 2 study, sponsored by Milton S. Hershey Medical Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT04003896 is a Phase 2 study that was terminated before completion, run by Milton S. Hershey Medical Center. The registered enrollment target is 4 participants.
The verdict
NCT04003896, a Phase 2 study, was terminated before completion, sponsored by Milton S. Hershey Medical Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
The prognosis of patients with recurrent, late-stage inoperable, or progressed biliary tract carcinoma (BTC) is generally poor. The goal of this clinical study is to determine the effectiveness and safety of abemaciclib in patients with late-stage or progressed BTC that has failed one line of chemotherapy.
Interventions
- DRUG Abemaciclib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2021-09-24 |
| Est. Completion | 2023-08-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04003896
The ClinicalTrials.gov registry entry for NCT04003896 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Milton S. Hershey Medical Center, which has 396 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Abemaciclib is the first listed.
NCT04003896 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04003896 about?
NCT04003896 is a clinical study titled "A Study to Evaluate Abemaciclib in Advanced Biliary Tract Carcinoma". The prognosis of patients with recurrent, late-stage inoperable, or progressed biliary tract carcinoma (BTC) is generally poor. The goal of this clinical study is to determine the effectiveness and safety of abemaciclib in patients with late-stage or progressed BTC that has failed one line of chemot...
What is the current status of trial NCT04003896?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2021-09-24. Estimated completion is 2023-08-15.
What interventions are being tested in trial NCT04003896?
The interventions under investigation include: Abemaciclib (DRUG).
Who is sponsoring clinical trial NCT04003896?
This trial is sponsored by Milton S. Hershey Medical Center, which has 396 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.